Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV‐Uninfected female subjects
Authors:
- 13 June 2014
- journal article
- pharmacogenomics
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (11) , 1290-1298
Abstract
This study evaluated the potential for a drug–drug interaction between HCV direct-acting antivirals sofosbuvir or ledipasvir and oral hormonal contraceptive (OC) norgestimate/ethinyl estradiol (norgestimate 0.18/0.215/0.25 mg with ethinyl estradiol 25 μg). This was a 112-day, open-label, fixed-sequence pharmacokinetic (PK) study in healthy female subjects that included a lead-in cycle (OC only; N = 21), cycle 1 (OC only; N = 15), cycle 2 (OC + sofosbuvir; N = 15), and cycle 3 (OC + ledipasvir; N = 15). Administration of sofosbuvir with OC did not alter PK of norelgestromin (primary norgestimate metabolite) or ethinyl estradiol. Small increases in norgestrel (secondary norgestimate metabolite) AUCtau (19%) and Ctau (23%) with sofosbuvir were noted. Ledipasvir did not impact PK of norelgestromin or norgestrel but modestly increased ethinyl estradiol Cmax (40%). Sofosbuvir, GS- 331007 (predominant circulating metabolite of SOF), and ledipasvir PK were similar to historical data. Pharmacodynamic markers luteinizing hormone, follicle-stimulating hormone, and progesterone values were generally comparable in all cycles. No loss in contraceptive efficacy is expected upon administration of sofosbuvir or ledipasvir/sofosbuvir with oral contraceptives containing norgestimate and ethinyl estradiol. The use of sofosbuvir or ledipasvir/sofosbuvir FDC with oral contraceptives is permitted.Keywords
This publication has 11 references indexed in Scilit:
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- The Effect of Atazanavir/Ritonavir on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy WomenAntiviral Therapy, 2010
- Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal ContraceptivesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co‐administered in healthy female subjectsBritish Journal of Clinical Pharmacology, 2008
- Pharmacokinetic Drug Interactions Involving 17??-EthinylestradiolClinical Pharmacokinetics, 2007
- The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptiveBritish Journal of Clinical Pharmacology, 2004
- The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptiveClinical Pharmacology & Therapeutics, 1999
- Can grapefruit juice influence ethinylestradiol bioavailability?Contraception, 1996